Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Oxalic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | THRB | P10828 | 1/20 | 0.56 |
| ▸ | MMP2 | P08253 | 3/20 | 0.42 |
| ▸ | CA12 | O43570 | 3/20 | 0.42 |
| ▸ | CA1 | P00915 | 3/20 | 0.42 |
| ▸ | CA2 | P00918 | 3/20 | 0.42 |
| ▸ | CA9 | Q16790 | 3/20 | 0.42 |
| ▸ | MMP9 | P14780 | 2/20 | 0.42 |
| ▸ | MMP1 | P03956 | 2/20 | 0.42 |
| ▸ | MMP3 | P08254 | 1/20 | 0.42 |
| ▸ | MMP8 | P22894 | 1/20 | 0.42 |
| ▸ | MMP13 | P45452 | 1/20 | 0.42 |
| ▸ | CA4 | P22748 | 1/20 | 0.37 |
| ▸ | FAHD1 | Q6P587 | 1/20 | 0.37 |
| ▸ | CES2 | O00748 | 1/20 | 0.33 |
| ▸ | CES1 | P23141 | 1/20 | 0.33 |
| ▸ | ANPEP | P15144 | 1/20 | 0.33 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.33 |
| ▸ | EPHX1 | P07099 | 3/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Oxalic Acid SCHEMBL29422639 | 1.00 | MEN1 (0.56) | MEN1KMT2ATHRBMMP2CA12 | |
| Oxalic Acid SCHEMBL965059 | 1.00 | MEN1 (0.56) | MEN1KMT2ATHRBMMP2CA12 | |
| Oxalic Acid SCHEMBL28517984 | 0.97 | MEN1 (0.53) | MEN1KMT2ATHRBMMP2CA12 | |
| Oxalic Acid SCHEMBL15263131 | 0.94 | MEN1 (0.56) | MEN1KMT2ATHRBMMP2CA12 | |
| Oxalic Acid SCHEMBL4019358 | 0.94 | MEN1 (0.56) | MEN1KMT2ATHRBMMP2CA12 | |
| Oxalic Acid SCHEMBL29186473 | 0.89 | THRB (0.43) | MEN1KMT2ATHRBMMP2CA12 | |
| Pyruvate SCHEMBL3172393 | 0.87 | CA4 (0.48) | MEN1KMT2ATHRBMMP2CA12 | |
| Malonic Acid SCHEMBL2174031 | 0.82 | CA4 (0.48) | MEN1KMT2ATHRBMMP2CA12 | |
| Acetic Acid SCHEMBL29253911 | 0.81 | MEN1 (0.53) | MEN1KMT2ATHRBMMP2CA12 | |
| Acetic Acid SCHEMBL10590524 | 0.81 | MEN1 (0.53) | MEN1KMT2ATHRBMMP2CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 147031 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260144783-A1 | COMPOSITION FOR PREVENTING OR TREATING PERIPHERAL NEUROPATHY, CONTAINING ISOQUINOLINE DERIVATIVE AS ACTIVE INGREDIENT | ALTMEDICAL CO., LTD. (KR) | 2026-05-28 | — | — | US | claimed |
| US-20260144847-A1 | VIBRIO CHOLERAE PROTEIN FOR USE AGAINST CANCER | LINNANE PHARMA AB (SE) | 2026-05-28 | — | — | US | claimed |
| US-20260144793-A1 | METHODS OF TREATING CANCER | AMGEN INC. (US) | 2026-05-28 | — | — | US | claimed |
| EP-4748859-A2 | CHEMICALLY AND PHOTOCHEMICALLY INITIATED CELL MEMBRANE BLEBBING TO INDUCE CELL VESICLE PRODUCTION, MODIFICATIONS THEREOF, AND USES THEREOF | The Regents of the University of California (US) | 2026-05-27 | — | — | EP | claimed |
| EP-3607938-B1 | PHARMACEUTICAL COMPOSITION | SOVIC BRKICIC LJILJANA (HR) | 2026-05-27 | — | — | EP | claimed |
| EP-4748449-A2 | USE OF SHORT CHAIN FATTY ACIDS IN CANCER PREVENTION | Temple University Of The Commonwealth System Of Higher Education (US) | 2026-05-27 | — | — | EP | claimed |
| CN-116209439-B | Cereblon protein modulators | Saint Jude Children's Research Hospital Ltd. (US) | 2026-05-26 | — | — | CN | claimed |
| CN-117180264-B | Application of schisandrin B in preparing analgesic | Mengyang Pharmaceutical (Shanghai) Co.,Ltd. (CN) | 2026-05-26 | — | — | CN | claimed |
| CN-122081491-A | Application of RECQL as target in preparation of products for treating and diagnosing gastric cancer | — | 2026-05-26 | — | — | CN | claimed |
| CN-122075411-A | Tripterine liposome, its combined medicine and its application in preventing and treating tumor | — | 2026-05-26 | — | — | CN | claimed |
| US-5945122-A | A LIPOSOME CONTAINING AN ENTRAPPED CISPLATIN COMPOUND HAVING A SURFACE COATING OF HYDROPHILILC POLYMER CHAINS ON INNER AND OUTER SURFACES; ANTITUMOR AND ANTICARCINOGENIC AGENT | SEQUUS PHARMACEUTICALS, INC. (US) | 1999-08-31 | — | — | US | claimed |
| EP-0929293-A1 | LIPOSOMES CONTAINING A CISPLATIN COMPOUND | SEQUUS PHARMACEUTICALS, INC. (US) | 1999-07-21 | — | — | EP | claimed |
| WO-1999001118-A9 | ANTIOXIDANT ENHANCEMENT OF THERAPY FOR HYPERPROLIFERATIVE CONDITIONS | ATHEROGENICS INC (US) | 1999-05-20 | — | — | WO | claimed |
| WO-1999001118-A2 | ANTIOXIDANT ENHANCEMENT OF THERAPY FOR HYPERPROLIFERATIVE CONDITIONS | ATHEROGENICS, INC. (US) | 1999-01-14 | — | — | WO | claimed |
| WO-1998039009-A1 | METHOD OF TREATING A TUMOR | SANOFI PHARMACEUTICALS, INC. (US) | 1998-09-11 | — | — | WO | claimed |
| WO-1998007409-A1 | LIPOSOMES CONTAINING A CISPLATIN COMPOUND | SEQUUS PHARMACEUTICALS, INC. (US) | 1998-02-26 | — | — | WO | claimed |
| US-5716988-A | READY-TO-USE; PARENTERAL ADMINISTERING | DEBIOPHARM S.A. (CH) | 1998-02-10 | — | — | US | claimed |
| CN-1154654-A | Pharmaceutically stable oxaliplatinum prepn. | DEBIOPHARM SA (CH) | 1997-07-16 | — | — | CN | claimed |
| EP-0393575-B1 | Neoplasia treatment compositions containing antineoplastic agent and side-effect reducing protective agent | SEARLE & CO (US) | 1994-03-16 | — | — | EP | claimed |
| EP-0393575-A1 | Neoplasia treatment compositions containing antineoplastic agent and side-effect reducing protective agent | G.D. Searle & Co. (US) | 1990-10-24 | — | — | EP | claimed |